Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption.
BACKGROUND
L-dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime. We report here a design of using D-phenylglycine to guard L-dopa for better absorption in the intestine via intestinal peptide transporter I (PepT1).


METHODS
D-phenylglycine was chemically attached on L-dopa to form D-phenylglycine-L-dopa as a dipeptide prodrug of L-dopa. The cross-membrane transport of this dipeptide and L-dopa via PepT1 was compared in brush-boarder membrane vesicle (BBMV) prepared from rat intestine. The intestinal absorption was compared by in situ jejunal perfusion in rats. The pharmacokinetics after i.v. and p.o. administration of both compounds were also compared in Wistar rats. The striatal dopamine released after i.v. administration of D-phenylglycine-L-dopa was collected by brain microdialysis and monitored by HPLC. Anti-Parkinsonism effect was determined by counting the rotation of 6-OHDA-treated unilateral striatal lesioned rats elicited rotation with (+)-methamphetamine (MA).


RESULTS
The BBMV uptake of D-phenylglycine-L-dopa was inhibited by Gly-Pro, Gly-Phe and cephradine, the typical PepT1 substrates, but not by amino acids Phe or L-dopa. The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10). The oral bioavailability of D-phenylglycine-L-dopa was 31.7 times higher than that of L-dopa in rats. A sustained releasing profile of striatal dopamine was demonstrated after i. v. injection of D-phenylglycine-L-dopa (50 mg/kg), indicated that D-phenylglycine-L-dopa might be a prodrug of dopamine. D-phenylglycine-L-dopa was more efficient than L-dopa in lowering the rotation of unilateral striatal lesioned rats (19.1 ± 1.7% vs. 9.9 ± 1.4%).


CONCLUSIONS
The BBMV uptake studies indicated that D-phenylglycine facilitated the transport of L-dopa through the intestinal PepT1 transporter. The higher jejunal permeability and the improved systemic bioavailability of D-phenylglycine-L-dopa in comparison to that of l-dopa suggested that D-phenylglycine is an effective delivery tool for improving the oral absorption of drugs like L-dopa with unsatisfactory pharmacokinetics. The gradual release of dopamine in brain striatum rendered this dipeptide as a potential dopamine sustained-releasing prodrug.
Wang
Chun-Li
CL
Taipei Medical University College of Pharmacy, 250 Wu-Hsing St,, Taipei, 110-31, Taiwan.
Fan
Yang-Bin
YB
Lu
Hsiao-Hwa
HH
Tsai
Tung-Hu
TH
Tsai
Ming-Cheng
MC
Wang
Hui-Po
HP
D000818:Animals; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D004298:Dopamine / Q000032:analysis; D004337:Drug Carriers / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005998:Glycine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology*; D007980:Levodopa / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use; D017551:Microdialysis; D008871:Microvilli / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy*; D000074011:Peptide Transporter 1; D051381:Rats; D017208:Rats, Wistar; D045442:Rotarod Performance Test; D027981:Symporters / Q000378:metabolism*; D022161:Transport Vesicles / Q000378:metabolism
D004337:Drug Carriers; D000074011:Peptide Transporter 1; C082186:SLC15A1 protein, human; D027981:Symporters; D007980:Levodopa; C008852:2-phenylglycine; D005998:Glycine; D004298:Dopamine
Neurol Clin. 1992 May;10(2):487-509
1584186
Neurol Sci. 2008 Dec;29 Suppl 5:S377-9
19381767
Pharm Res. 1989 Jan;6(1):66-70
2717522
Adv Drug Deliv Rev. 2007 Sep 30;59(11):1103-20
17900749
Nat Rev Neurosci. 2001 May;2(5):325-34
11331916
Pharmacol Toxicol. 2002 Jun;90(6):285-96
12403049
Br J Clin Pharmacol. 1993 Mar;35(3):243-50
8471400
J Pharmacol Exp Ther. 2008 Nov;327(2):432-41
18713951
J Med Chem. 2006 Jun 15;49(12):3636-44
16759105
Adv Drug Deliv Rev. 2004 Jun 23;56(10):1437-52
15191791
J Chem Inf Model. 2008 Jan;48(1):233-41
18092768
Eur J Neurosci. 2005 Aug;22(3):735-44
16101755
Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S21-4
19131037
N Engl J Med. 2008 Dec 4;359(23):2468-76
19052127
Parkinsonism Relat Disord. 1998 Aug;4(2):59-60
18591089
Eur Neurol. 2009;62(1):1-8
19407449
Pharm Res. 1988 Oct;5(10):651-4
3244618
Nat Rev Neurosci. 2008 Sep;9(9):665-77
18714325
Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G697-704
11518682
J Pharm Pharmacol. 1996 Mar;48(3):270-6
8737052
J Pharmacol Exp Ther. 2003 Feb;304(2):781-91
12538834
J Pharm Sci. 1992 Jan;81(1):21-5
1619565
Biochem Pharmacol. 1986 Jun 1;35(11):1781-6
3718527
Eur J Pharm Sci. 2004 Jan;21(1):53-60
14706811
Neurology. 2009 May 26;72(21 Suppl 4):S1-136
19470958
Nutr Rev. 1994 Feb;52(2 Pt 1):51-8
8183469
Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):887-905
19519280
J Theor Biol. 1988 Mar 7;131(1):93-106
3419195
Brain Res. 1993 Oct 29;626(1-2):167-74
8281427
Pharm Res. 2009 Jan;26(1):40-50
18784906
Eur J Pharm Biopharm. 2003 Jan;55(1):71-6
12551706
Behav Brain Res. 2005 Jul 1;162(1):1-10
15922062
J Pharmacokinet Biopharm. 1980 Oct;8(5):509-34
7252794